Next Article in Journal
One Scaffold, Two Conformations: The Ring-Flip of the Messenger InsP8 Occurs under Cytosolic Conditions
Previous Article in Journal
Tyrosinase Magnetic Cross-Linked Enzyme Aggregates: Biocatalytic Study in Deep Eutectic Solvent Aqueous Solutions
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomolecules
Volume 13
Issue 4
10.3390/biom13040644
biomolecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Alpha-Synuclein mRNA Level Found Dependent on L444P Variant in Carriers and Gaucher Disease Patients on Enzyme Replacement Therapy

by
Paweł Dubiela
1,2,†,
Paulina Szymańska-Rożek
3,†,
Andrzej Eljaszewicz
1,
Patryk Lipiński
4,
Piotr Hasiński
5,
Dorota Giersz
1,
Alicja Walewska
1,
Marlena Tynecka
1,
Marcin Moniuszko
1 and
Anna Tylki-Szymańska
4,*
1
Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, 15-269 Bialystok, Poland
2
Department of Pathophysiology and Allergy Research, Medical University of Vienna, 1090 Vienna, Austria
3
Faculty of Mathematics, Informatics and Mechanics, University of Warsaw, 02-097 Warsaw, Poland
4
Department of Pediatrics, Nutrition and Metabolic Diseases, The Children’s Memorial Health Institute, 04-730 Warsaw, Poland
5
Department of Internal Medicine and Gastroenterology, Municipal Hospital, 43-100 Tychy, Poland
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Biomolecules 2023, 13(4), 644; https://doi.org/10.3390/biom13040644
Submission received: 24 February 2023 / Revised: 31 March 2023 / Accepted: 1 April 2023 / Published: 3 April 2023
(This article belongs to the Section Molecular Biomarkers)
Browse Figures
Review Reports Versions Notes

Abstract

Gaucher disease (GD) is the most frequent sphingolipidosis, caused by biallelic pathogenic variants in the GBA1 gene encoding for β-glucocerebrosidase (GCase, E.C. 3.2.1.45). The condition is characterized by hepatosplenomegaly, hematological abnormalities, and bone disease in both non-neuronopathic type 1 (GD1) and neuronopathic type 3 (GD3). Interestingly, GBA1 variants were found to be one of the most important risk factors for the development of Parkinson’s disease (PD) in GD1 patients. We performed a comprehensive study regarding the two most disease-specific biomarkers, glucosylsphingosine (Lyso-Gb1) and α-synuclein for GD and PD, respectively. A total of 65 patients with GD treated with ERT (47 GD1 patients and 18 GD3 patients), 19 GBA1 pathogenic variant carriers (including 10 L444P carriers), and 16 healthy subjects were involved in the study. Lyso-Gb1 was assessed by dried blood spot testing. The level of α-synuclein as an mRNA transcript, total, and oligomer protein concentration were measured with real-time PCR and ELISA, respectively. α-synuclein mRNA level was found significantly elevated in GD3 patients and L444P carriers. GD1 patients, along with GBA1 carriers of an unknown or unconfirmed variant, as well as healthy controls, have the same low level of α-synuclein mRNA. There was no correlation found between the level of α-synuclein mRNA and age in GD patients treated with ERT, whereas there was a positive correlation in L444P carriers.

1. Introduction

Gaucher disease (GD) is the most frequent sphingolipidosis, caused by biallelic pathogenic variants in the GBA1 gene. More than 400 GBA1 pathogenic variants have been described so far, some of them, such as c.1226A>G (p.Asn409Ser; N370S), c.1448T>C (p.Leu483Pro; L444P), c.84dup, c.115+1G>A (IVS2+1G>A) being responsible for 90% of cases among Ashkenazi Jews population and 60% of non-Ashkenazi patients [1,2,3]. GBA1 defects lead to β-glucocerebrosidase (GCase) enzyme deficiency, which results in accumulation of its substrate, glucosylceramide (GlcCer, Gb1), mostly in the monocyte-macrophage system [4]. The disease course is clinically variable and depends on specific GBA1 variants. Three clinical forms have been identified. The most common form, type 1 (GD1), is believed not to cause neurological damage, whereas neuronopathic forms, type 2 (GD2) and 3 (GD3), are characterized by progressive neurological impairment [5].
Glucosylsphingosine (Lyso-Gb1) is a deacylated form of glucosylceramide. In GD patients, Lyso-Gb1 plasma concentrations are found to be markedly increased above the cut-off level (12–14 ng/mL), compared to healthy individuals [6]. The association between patients genotypes and Lyso-Gb1 levels has also been reported. GD patients homozygous for the L444P variant had higher Lyso-Gb1 levels (median, 184.5 ng/mL) than those with the N370S variant on at least one GBA1 allele (median, 143.1 ng/mL) [7]. Moreover, the brain levels of Lyso-Gb1 were shown to be 22–51 times and 38–694 times higher in patients with GD3 and GD2, respectively, in comparison to healthy individuals. At the same time, the brain levels of Lyso-Gb1 in GD1 patients were found within the normal range and were comparable to those in healthy subjects, thus suggesting that elevated Lyso-Gb1 levels may contribute to the neurological manifestations characteristic of neuronopathic GD [8]. Therefore, it is not surprising that Lyso-Gb1 is believed to be the most reliable biomarker currently available for the diagnosis, prognosis, and treatment monitoring of GD patients, as reviewed by Revel-Vilk et al. [9].
Parkinson’s disease (PD) is the second most common neurodegenerative disorder, with an average age of 62 years at diagnosis and a risk of about 3% to 4% in developed countries [10,11]. Aside from the involvement of several commonly known neurotransmitters, including the cholinergic, noradrenergic, and serotonergic pathways [12,13,14,15], there is growing evidence of the genetic background [16]. The formation of intracellular deposits of proteins and lipids that precede neuronal damage is believed to be the most critical factor responsible for PD development. The main players in this pathology are the Lewy bodies, with deposits of α-synuclein (α-SNCA), whose robust presence was found in neurodegenerative structures [17,18,19,20,21]. It is in line with the fact that SNCA pathogenic variants are commonly associated with PD [22]. Those two discoveries led to the pathological staging of the disease proposed by Braak et al. [23]. Even now, the fact that α-SNCA deposition occurs early in PD is applied in immunohistochemical tests and is referred to as the gold standard in the neuropathological evaluation of PD [24].
The α-SNCA protein consists of 140 amino acid residues and reveals a sophisticated nature. Since in aqueous solutions it does not have a defined structure, it was referred to as a “natively unstructured protein” [25]. However, it has α-helical structures upon binding to negatively charged lipids, such as phospholipids present in the cellular membranes [26]. Unfolded (native) monomeric α-SNCA is able to aggregate into oligomeric species that can be stabilized by β-sheet-like interactions. Such oligomers can further transform into higher molecular weight, insoluble fibrils, seen in different synucleinopathies [27].
The association of GBA1 variants with PD and dementia (GBA1-associated Parkinson’s disease) has been extensively studied over the past few years. Although GD1 is not associated with neurological impairment, there is an approximately 26-fold higher life-time risk of developing PD compared to the general population. Specifically, from 5% to 7% of GD1 patients may develop PD before the age of 70 and 9 to 12% before the age of 80, with a mean age of 57 years at the onset [28]. On the contrary, the glucocerobrosidase E326K variant is known to predispose to PD, but does not cause GD [29]. There is scarce information about GD3 patients and PD, due to the low number of diagnosed cases and reduced life expectancy [30]. Interestingly, carriers of GBA1 pathogenic variants are also at a higher risk of developing PD [5,31,32]. Further studies are aimed at explaining this phenomenon. It was shown that Lyso-Gb1 correlated with elevated α-synuclein levels in neurons from patients with neuronopathic GD or PD and also promoted the formation of α-SNCA oligomers [33,34,35]. Although the available data provides some insight regarding the potential roles of Lyso-Gb1 and α-SNCA in the interplay between GD and PD, there are still puzzles missing from the picture.
Therefore, we aimed to provide comprehensive data and find possible interactions between GBA1 pathogenic variants, including GD1 and GD3 patients and obligatory carriers from their families, Lyso-Gb1 concentration, and α-SNCA, by considering total protein concentration, oligomer concentration, and SNCA mRNA transcript level.

2. Materials and Methods

2.1. Patients and Blood Samples

A total of 65 patients with GD treated with ERT, 19 GBA1 pathogenic variant carriers, and 16 healthy subjects were recruited to the study. The protocol of the study was approved by the local Ethical Committee of The Children’s Memorial Health Institute, Warsaw, Poland (number 51/KB/2019). A written, informed consent was obtained from all participants. The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki.
Blood samples were obtained at one point in time from GD patients undergoing their annual clinical follow-up visit, combined with the biochemical analysis. In addition, family members and healthy subjects were invited to participate in the study. The clinical interview was standardized and performed by a single experienced clinician. Lyso-Gb1 levels in plasma were measured using high-pressure liquid chromatography–tandem mass spectrometry at Archimed Life Sciences Vienna, as previously described [7]. Genetic data were retrieved from the medical records of GD patients and acquired for healthy subjects at Archimed Life Sciences Vienna [7]. All the samples were blinded and sent for α-synuclein laboratory analysis in the coded format.

2.2. Biobanking

All the blood samples analyzed in the study were collected, transferred, and stored at the Medical University of Bialystok Biobank, Poland (member of BBMRI.pl, a national node of the European Biobank Network, BBMRI-ERIC), according to the standard operating procedure for biological materials. Briefly, the blood was centrifuged at room temperature for 5 min at 400× g to separate plasma. Next, plasma specimens were centrifuged at 4 °C for 5 min at 1200× g to remove residual cells. Aliquoted samples were biobanked at −80 °C in a controlled environment. Peripheral blood mononuclear cells (PBMCs) were isolated from plasma-depleted blood samples by means of density gradient centrifugation (Pancoll). Freshly isolated cells (1 million) were lysed using RLT buffer (Qiagen, Hilden, Germany) and biobanked at −80 °C. The remaining cells were cryopreserved in a freezing medium (Fetal Bovine Serum, PAA supplemented with DMSO, Sigma-Aldrich, St. Louis, MO, USA) and stored in LN2.

2.3. α-Synuclein mRNA Analysis

Total RNA was isolated from PBMC lysates using the #RNeasy Mini Kit isolation kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. Quantity and quality of RNA assessments were performed using a UV/VIS spectrophotometer, the NanoDrop 2000c (Thermo Fisher Scientific, Inc., Waltham, MA, USA). The RNA was reverse transcribed using High-Capacity RNA-to-cDNA kit (Applied Biosystems, Waltham, MA, USA; Thermo Fisher Scientific, Inc.) according to the manufacturer’s instructions. SNCA Hs00240906 gene expression and housekeeping gene (GAPDH Hs02786624, Thermo Fisher Scientific) were analyzed with Taq probe (TaqManTM Universal Master Mix, with UNG, Applied Biosystems; Thermo Fisher Scientific, Inc.) using StepOne Plus Real-Time System (Applied Biosystems; Thermo Fisher Scientific, Inc.). Each sample was analyzed in triplicate.

2.4. α-Synuclein Total and Oligomer Protein Concentration

The total α-SNCA protein concentration was measured from the plasma with Human alpha-synuclein DuoSet ELISA (R & D Systems Europe, Ltd., Minneapolis, MN, USA) according to the manufacturer’s protocol. The detection range of the test is 0.157 ng/mL–10 ng/mL. For the samples exceeding the range, a signal threshold value of 0.157 ng/mL and 20 ng/mL was assumed. α-SNCA oligomer concentration was assessed in the plasma using a commercially available human alpha synuclein oligomer (A-SNCO) ELISA kit (MyBiosource.com), according to the manufacturer’s protocol. The detection range of the test is 0.625 ng/mL–20 ng/mL. The reaction plates were analyzed with an automated light absorption reader (Ledetec). The results were calculated according to the standard curve using MicroWin2000 software (Baton Rouge, LA, USA).

2.5. Statistical Analysis

The data were first checked for normality with the Shapiro–Wilk test. Since in the vast majority of groups the distributions were not normal, a proper variant of the t-test was used to assess statistical differences in distributions. “Raw” p-values of these comparisons are reported on the box-plots, if only they are less than 0.05. However, to minimize the probability of reporting insignificant results as significant, we adjust the p-values with the Benjamini–Hochberg correction and report as significant only those p-values that are less than the largest p-value that is less than its Benjamini–Hochberg critical value (see [36]). Finally, the data were investigated for age correlations in the five groups for all four markers. The coefficients of Pearson’s linear correlation were then assessed for statistical significance with t-tests. Statistical analysis was performed in RStudio, and figures were drawn in Gnuplot.

3. Results

3.1. Patients’ Characteristics

A total of 65 Polish patients with GD, 47 of type 1 and 18 of type 3, were enrolled in the study. All the patients displayed a decreased activity of β-glucocerebrosidase, combined with genetic confirmation (detection of GBA1 biallelic pathogenic variants). Regarding patients’ genotype, the entire GD3 population consisted of L444P homozygotes, and GD1 patients presented various variants, see Table 1.
A total of 19 carriers of GBA1 pathogenic variants and 16 healthy individuals served as comparators. Among the 19 GBA1 carriers, 10 were identified as L444P variant carriers, and the remaining nine have either N370S or an unknown GBA1 pathogenic variant. Most of the patients were adults, with one adolescent among the carriers and three adolescents in the group of GD1 patients. All the patients with GD were treated with ERT. Basic demographic data are presented in Table 2. Due to the rarity and nature of the disease, it was not possible to match patients in terms of age, so GD3 patients were significantly younger.

3.2. Lyso-Gb1 Concentration

According to the threshold in the Archimed Life Science Lab, Lyso-Gb1 levels less than 14 ng/mL were considered normal. All patients diagnosed with GD had Lyso-Gb1 levels higher than this threshold. GD1 and GD3 patients had median values of 71.5 ng/mL and 64.6 ng/mL (p > 0.05), respectively. The median biomarker concentration was significantly higher in GD patients than in GBA1 variant carriers (median of 7.51 ng/mL, p < 10−9) and healthy control subjects (8.49 ng/mL, p < 10−8). There was no statistically significant difference between the two healthy cohorts. Elevated Lyso-Gb1 levels were found in one healthy subject and seven GBA1 variant carriers (Figure 1, Table 2).

3.3. SNCA Gene Expression

The levels of SNCA mRNA transcript were substantially higher in GD3 patients and the L444P carriers (with medians of 77.48 and 66.42 (2−ΔcT), respectively). Healthy controls, as well as GD1 patients and N370S carriers, had very low levels of SNCA mRNA transcript, with medians of 0.83, 047, and 0.52 (2−ΔcT), respectively (Figure 2, Table 2). The difference in SNCA mRNA transcript level between carriers of L444P on at least one GBA1 allele and any other tested group was found to be statistically significant. Figure 2 is the only figure where GD patients were divided into GD1 and GD3 subgroups and carriers were divided into “L444P mutation carriers” and “unknown mutation carriers”. This is because of the significantly different results obtained for the pairs of subgroups: GD1/GD3, and “L444P mutation carrier”/“unknown mutation carrier”. Note that all other markers analyzed were statistically equal for these two pairs of subgroups.

3.4. α-SNCA Total Protein Level

The median total α-SNCA protein concentration was found to be the highest in the control group (1.34 ng/mL). Both GD patients and GBA1 carriers had medians of 0.16 and 0.54 ng/mL, respectively (Figure 3, Table 2). The difference between GD patients and the control group appeared to be statistically significant (p-value of 0.0075), but since we had to account for multiple comparisons, this p-value after the adjustment was not assessed as significant.

3.5. α-SNCA Oligomer Concentration

There were no statistically significant differences in the levels of oligomer α-synuclein between GD patients, GBA1 carriers, and the control group. The medians were as follows: 1.81, 1.69, and 2.08 ng/mL, respectively (Figure 4, Table 2).

3.6. Correlations with Age

The measured factors, namely: Lyso-Gb1, SNCA transcript level, α-SNCA protein, and oligomer concentration, were checked for linear correlation with age in five groups: GD1, GD3, unknown GBA1 variant carriers, L444P carriers, and the healthy control. The only correlations found were as follows: total α-SNCA protein level among GD3 patients (r = −0.52, p = 0.029), SNCA mRNA level among the carriers of an unknown mutation (r = −0.6, p = 0.19), and SNCA mRNA level in L444P mutation carriers (r = 0.74, p = 0.039) (Supplementary Figure S1, Supplementary Table S2). All other variables in the tested cohorts were found to be uncorrelated with age. The results of the whole analysis are presented in Supplementary Figure S1 and Supplementary Table S1.

4. Discussion

Since the GBA1 pathogenic variants are the best described risk factors for Parkinson’s disease [5,31,32], we aimed to understand the molecular level relevance of the most commonly reported GBA1 variants, N370S and L444P, and performed the study on Lyso-Gb1 and α-synuclein as the most relevant markers of Gaucher and Parkinson’s disease, respectively. We found elevated mRNA SNCA level among GD3 patients and L444P mutation carriers compared to other tested cohorts, with no concomitant elevation in α-synuclein protein level or increase in its oligomerization.
The role of Lyso-Gb1 as the diagnostic marker in GD patients’ management is well established [9]. Interestingly, no statistically significant difference in Lyso-Gb1 levels was found among treated patients with GD1 and GD3. This observation can be somehow surprising since the Lyso-Gb1 level reflects the severity of the disease [7]. Based on the recently reported studies, it was shown that Lyso-Gb1 is useful for treatment monitoring [37]. There was a clear correlation between certain genotypes and the patients who were naïve to therapy, especially with GD3, which had the highest biomarker concentrations [37]. On the other hand, as shown by Dekker et al., only among N370S homozygotes was there a clear correlation between disease severity and plasma Lyso-Gb1 concentrations [6]. The reported outcomes show differences caused not only by genotypic variations among the study groups but also reflect the ERT impact. It has recently been shown by our group that Lyso-Gb1 correlates with the response to the treatment measured by chitotriosidase activity only in some ranges of dosing or for splenectomized patients. The coefficient of determination, R2, follows a trend, increasing steadily with dosing, then suddenly dropping to 0.16 for patients treated with high doses (>35 U/kg bm/every other week). Therefore, one of the strengths and limitations of our study is its intrinsic heterogeneity. Patients were treated with different doses of ERT (15–60 U/kg, on average 30 U/kg bm/every other week). Another interesting finding is the elevated level of Lyso-Gb1 among L444P carriers. Individuals from the cohort exceeded the threshold level (14 ng/mL) and in one of the cases described in this paper, the concentration was more than three times higher (47 ng/mL).
One of the revolutions of the last decade was the finding of GBA1 pathogenic variants as the most important genetic predisposing risk factor for PD development [38,39]. At the same time, the role of α-SNCA in the etiopathogenesis of PD was well characterized, but there was no clear link on how GBA1 defects can be a risk factor for synucleinopathies. The link between GBA1 pathogenic variants (e.g., N370S, L444P) and the accumulation of α-synuclein and formation of its aggregates can be explained by dysfunctions of proteolysis machinery due to ER stress and defects of chaperone-mediated autophagy [40]. Loss of GCase function leads to accumulation of lipids such as Gb1 and Lyso-Gb1, which directly interact with and stabilize α-synuclein oligomers in the lysosomal compartment. The consequent α-synuclein accumulation inhibits ER-to-Golgi GCase trafficking but also causes general lysosomal dysfunction, defective mitophagic and autophagic clearance pathways, and Ca2+ homeostasis dysfunction [40].
Our data provide some interesting insights. There was no increase in the concentration of α-synuclein oligomers among GD patients in comparison to healthy controls and GBA1 variant carriers. These results are contrary to the previous study showing an increased dimerization of α-synuclein in the erythrocytes of GD patients [41]. The results should be compared with caution since the authors narrowed the conclusions to the analysis of red blood cells as they were not able to detect α-synuclein in any other tissue samples. In another study, by Pchelina et al., there was found to be an increased concentration of α-SNCA in GD patients compared to the control group. However, this difference was found not to be specific for GD patients but also presented for other lysosomal storage disorders. The authors also found the effect of the ERT duration on the total amount of α-SNCA and the age to be negatively correlated with the protein oligomerization [42].
The second part of our approach aimed to identify differences in the total concentration of α-synuclein. We found slightly elevated levels of total α-SNCA protein among healthy controls in comparison with GD patients; however, in our statistical model, the difference was not significant. There are not enough literature data to refer our observations to. The results from the mice model showed an increase in α-SNCA concentration in the neurons of individuals with GCase deficiency. The authors suggested that the increase in protein concentration, and thus α-SNCA polymerization, leads to neurotoxicity [43]. Another study performed on samples from cerebrospinal fluid among GBA1 pathogenic variant carriers revealed the opposite results, with decreased α-SNCA levels [44]. Our data, obtained from blood samples, suggest that there is a moderately negative correlation between total α-SNCA concentration and age among GD3 patients. These results partially support the observation made by Lerche et al. and Pchelina et al. indicating that with time and duration of ERT treatment, the level of α-SNCA concentration decreases and protein oligomerization is not promoted [42,44]. Perhaps this could be the case in our study, where the majority of GD3 patients in our cohorts were diagnosed and started treatment very early, continuing to receive ERT for over 20 years (data not shown).
The most interesting observations are coming from the results showing the elevated mRNA SNCA level among GD3 patients and L444P carriers compared to other tested cohorts.
The elevated mRNA SNCA level was also previously reported by Chiba-Falek et al. in samples from the brains of sporadic PD patients [45]. The authors concluded that the obtained results suggest that elevated expression levels of SNCA-mRNA are found in the affected regions of the PD brain and support the hypothesis that increases in α-synuclein expression are associated, among other factors, with the development of sporadic PD.
L444P variant has been previously associated with PD development in various ethnic groups [46,47,48,49,50,51,52,53,54,55,56,57]. However, Becker-Cohen et al. have recently reported a study on the comprehensive assessment of prodromal parkinsonian features in 98 carriers (including 71 carriers of the N370S variant) of GD. L444P variant carriers exhibited the highest percentage of abnormal clinical tests assessing various domains of PD compared to N370S variant carriers [57]. However, there are some contradictory results on the presence of this pathogenic variant in early or late forms of PD [47,58,59]. Our data showed not only an elevated mRNA concentration but also a positive correlation of this factor with age. This, in turn, means that the SNCA expression level is increasing, but this does not correspond with either the total or oligomer α-SNCA concentration level. There is the possibility that protein is stored in the cells and therefore was not caught by our methods, as suggested by Barbour et al. [60]. Another hypothesis could be that the translation process is disrupted by proteases/regulators. It was shown that α-synuclein binds its own mRNA and prevents the initiation of translation at least to some extent [61,62].
When we add the results from unknown GBA1 variant carriers showing a negative correlation with age, i.e., a decrease in the mRNA concentration with aging, we can speculate why some researchers observe the decrease and others—the increase in α-SNCA, depending on the type of the sample, time, and treatment duration [41,42,43]. Our data also add the type of mutation to the picture’s complexity. If we consider the results of marker-age correlation analysis also for GD patients, we could be entitled to formulate a hypothesis about the effect of ERT for GD on the mRNA level of α-synuclein. In patients of both GD types (i.e., those having the L444P variant and those carrying another GBA1 variant), no correlation between the mRNA level and age was found. However, a strong age correlation was found for GBA1 carriers, who obviously are not treated for GD: unknown GBA1 variant carriers have mRNA levels that are negatively correlated with age, whereas L444P GBA1 carriers accumulate the transcript material of α-synuclein with age. Probably the presence of the L444P variant in the GBA1 gene can be a hint for searching for a further metabolic link between GD and an increased likelihood of PD. As proposed in the knockout mice model, L444P variant and accompanying α-synuclein accumulation leads the nigrostriatal dopamine neurons to an increased dopaminergic mitochondrial neurotoxin susceptibility, and thus plays dual physiological roles in the survival of the cells critically involved in parkinsonism [61]. Why the L444P variant upregulates SNCA mRNA expression with no clear link between SNCA mRNA transcript and total/oligomer α-SNCA protein level remains to be further studied.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/biom13040644/s1, Figure S1: Scatter plot of age (x-axis) and biomarkers (Lyso-Gb1, α-SNCA mRNA level, α-SNCA total protein concentration and oligomer concentration). Different point types indicate different subgroups. Table S1: Pearson linear correlation coefficient between the given marker (Lyso-Gb1, SNCA mRNA level, α-SNCA total protein concentration and oligomer concentration) and age in the following groups: GD1, GD3, unknown mutation carriers, L444P carriers, and control.

Author Contributions

The project outline was drafted by P.D., P.S.-R., and A.T.-S. The experiments were performed by P.D., P.S.-R., A.E., P.L., P.H., D.G., A.W., M.T., M.M., and A.T.-S. Data analysis and interpretation were completed by P.D., P.S.-R., A.E., P.L., P.H., D.G., A.W., M.T., M.M., and A.T.-S. All the authors (P.D., P.S.-R., A.E., P.L., P.H., D.G., A.W., M.T., M.M., and A.T.-S.) provided input to drafting the article and revised it critically for important intellectual content and gave final approval of the version to be published. All authors have read and agreed to the published version of the manuscript.

Funding

This work was funded by the Polish Association of Families with Gaucher Disease and carried out at The Children’s Memorial Health Institute.

Institutional Review Board Statement

The study was approved by the local Ethical Committee of The Children’s Memorial Health Institute, Warsaw, Poland (number 51/KB/2019).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

All data generated or analysed during this study are included in this published article.

Acknowledgments

We would like to thank David C. Kasper from Archimed Life Sciences for providing us the opportunity to test Gaucher pathogenic variant mutation carriers. We thank patients with Gaucher disease for participating in the study and the Polish Association of Families with Gaucher Disease, with special thanks to its head, Blazej Jelonek, for support. We are thankful to Maria Szkolmowska for taking samples from patients and preliminary preparation of material for shipment. We also thank Karolina Zwirbulis from English point for her language editing and Grzegorz Wegrzyn for his comments and suggestions to the manuscript text.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Koprivica, V.; Stone, D.L.; Park, J.K.; Callahan, M.; Frisch, A.; Cohen, I.J.; Tayebi, N.; Sidransky, E. Analysis and Classification of 304 Mutant Alleles in Patients with Type 1 and Type 3 Gaucher Disease. Am. J. Hum. Genet. 2000, 66, 1777–1786. [Google Scholar] [CrossRef] [PubMed]
  2. Horowitz, M.; Wilder, S.; Horowitz, Z.; Reiner, O.; Gelbart, T.; Beutler, E. The human glucocerebrosidase gene and pseudogene: Structure and evolution. Genomics 1989, 4, 87–96. [Google Scholar] [CrossRef] [PubMed]
  3. Stirnemann, J.; Belmatoug, N.; Camou, F.; Serratrice, C.; Froissart, R.; Caillaud, C.; Levade, T.; Astudillo, L.; Serratrice, J.; Brassier, A.; et al. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int. J. Mol. Sci. 2017, 18, 441. [Google Scholar] [CrossRef] [PubMed]
  4. Brady, R.O.; Kanfer, J.N.; Bradley, R.M.; Shapiro, D. Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher’s disease. J. Clin. Investig. 1966, 45, 1112–1115. [Google Scholar] [CrossRef] [PubMed]
  5. Sidransky, E. Gaucher disease: Insights from a rare Mendelian disorder. Discov. Med. 2012, 14, 273–281. [Google Scholar]
  6. Dekker, N.; van Dussen, L.; Hollak, C.E.M.; Overkleeft, H.; Scheij, S.; Ghauharali, K.; van Breemen, M.J.; Ferraz, M.J.; Groener, J.E.M.; Maas, M.; et al. Elevated plasma glucosylsphingosine in Gaucher disease: Relation to phenotype, storage cell markers, and therapeutic response. Blood 2011, 118, e118–e127. [Google Scholar] [CrossRef]
  7. Rolfs, A.; Giese, A.K.; Grittner, U.; Mascher, D.; Elstein, D.; Zimran, A.; Böttcher, T.; Lukas, J.; Hübner, R.; Gölnitz, U.; et al. Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease Patients. PLoS ONE 2013, 8, e79732. [Google Scholar] [CrossRef]
  8. Orvisky, E.; Park, J.K.; LaMarca, M.E.; Ginns, E.I.; Martin, B.M.; Tayebi, N.; Sidransky, E. Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: Correlation with phenotype and genotype. Mol. Genet. Metab. 2002, 76, 262–270. [Google Scholar] [CrossRef]
  9. Revel-Vilk, S.; Fuller, M.; Zimran, A. Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review. Int. J. Mol. Sci. 2020, 21, 7159. [Google Scholar] [CrossRef]
  10. Brooks, D.J. The early diagnosis of Parkinson’s disease. Ann. Neurol. 1998, 44, S10–S18. [Google Scholar] [CrossRef]
  11. Bergman, H.; Deuschl, G. Pathophysiology of Parkinson’s disease: From clinical neurology to basic neuroscience and back. Mov. Disord. 2002, 17, S28–S40. [Google Scholar] [CrossRef] [PubMed]
  12. Wolters, E.C. Non-motor extranigral signs and symptoms in Parkinson’s disease. Park. Relat. Disord. 2009, 15, S6–S12. [Google Scholar] [CrossRef] [PubMed]
  13. Halliday, G.; Lees, A.; Stern, M. Milestones in Parkinson’s disease-Clinical and pathologic features. Mov. Disord. 2011, 26, 1015–1021. [Google Scholar] [CrossRef]
  14. Jellinger, K.A. Neuropathology of sporadic Parkinson’s disease: Evaluation and changes of concepts. Mov. Disord. 2012, 27, 8–30. [Google Scholar] [CrossRef]
  15. Buddhala, C.; Loftin, S.K.; Kuley, B.M.; Cairns, N.J.; Campbell, M.C.; Perlmutter, J.S.; Kotzbauer, P.T. Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease. Ann. Clin. Transl. Neurol. 2015, 2, 949–959. [Google Scholar] [CrossRef] [PubMed]
  16. Singleton, A.; Hardy, J. The Evolution of Genetics: Alzheimer’s and Parkinson’s Diseases. Neuron 2016, 90, 1154–1163. [Google Scholar] [CrossRef]
  17. Moore, D.J.; West, A.B.; Dawson, V.L.; Dawson, T.M. Molecular pathophysiology of Parkinson’s disease. Ann. Rev. Neurosci. 2005, 28, 57–87. [Google Scholar] [CrossRef]
  18. Cookson, M.R. α-Synuclein and neuronal cell death. Mol. Neurodegener. 2009, 4, 4–9. [Google Scholar] [CrossRef]
  19. Beach, T.G.; Adler, C.H.; Sue, L.I.; Vedders, L.; Lue, L.; White Iii, C.L.; Akiyama, H.; Caviness, J.N.; Shill, H.A.; Sabbagh, M.N.; et al. Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010, 119, 689–702. [Google Scholar] [CrossRef]
  20. Coon, E.A.; Singer, W. Synucleinopathies. Continuum 2020, 26, 72–92. [Google Scholar] [CrossRef]
  21. Hallacli, E.; Kayatekin, C.; Nazeen, S.; Wang, X.H.; Sheinkopf, Z.; Sathyakumar, S.; Sarkar, S.; Jiang, X.; Dong, X.; Di Maio, R.; et al. The Parkinson’s disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability. Cell 2022, 185, 2035–2056.e33. [Google Scholar] [CrossRef]
  22. Polymeropoulos, M.H.; Lavedan, C.; Leroy, E.; Ide, S.E.; Dehejia, A.; Dutra, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson’s Disease. Science 1997, 276, 2045–2047. [Google Scholar] [CrossRef] [PubMed]
  23. Braak, H.; Del Tredici, K.; Rüb, U.; de Vos, R.A.I.; Jansen Steur, E.N.; Braak, E. Staging of brain pathology related to sporadic Par-kinson’s disease. Neurobiol. Aging 2003, 24, 197–211. [Google Scholar] [CrossRef] [PubMed]
  24. Ganguly, U.; Singh, S.; Pal, S.; Agrawal, B.K.; Saini, R.V.; Chakrabarti, S. Alpha-synuclein as a Biomarker of Parkinson’s Disease: Good, but Not Good Enough. Front. Aging Neurosci. 2021, 13, 702639. [Google Scholar] [CrossRef] [PubMed]
  25. Weinreb, P.H.; Zhen, W.; Poon, A.W.; Conway, K.A.; Lansbury, P.T. NACP, a protein implicated in Alzheimer’s disease and learning, is natively unfolded. Biochemistry 1996, 35, 13709–13715. [Google Scholar] [CrossRef]
  26. Pfefferkorn, C.M.; Jiang, Z.; Lee, J.C. Biophysics of α-synuclein membrane interactions. Biochim. Biophys. Acta 2012, 1818, 162–171. [Google Scholar] [CrossRef]
  27. Uversky, V.N. Amyloidogenesis of Natively Unfolded Proteins. Curr. Alzheimer Res. 2008, 5, 260–287. [Google Scholar] [CrossRef]
  28. Rosenbloom, B.; Balwani, M.; Bronstein, J.M.; Kolodny, E.; Sathe, S.; Gwosdow, A.R.; Taylor, J.S.; Cole, J.A.; Zimran, A.; Weinreb, N.J. The incidence of Parkinsonism in patients with type 1 Gaucher disease: Data from the ICGG Gaucher Registry. Blood Cells Mol. Dis. 2011, 46, 95–102. [Google Scholar] [CrossRef]
  29. Duran, R.; Mencacci, N.E.; Angeli, A.V.; Shoai, M.; Deas, E.; Houlden, H.; Mehta, A.; Hughes, D.; Cox, T.M.; Deegan, P.; et al. The glucocerobrosidase E326K variant predisposes to Parkinson’s disease, but does not cause Gaucher’s disease. Mov. Disord. 2012, 28, 232–236. [Google Scholar] [CrossRef]
  30. Tylki-Szymańska, A.; Vellodi, A.; El-Beshlawy, A.; Cole, J.A.; Kolodny, E. Neuronopathic Gaucher disease: Demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry. J. Inherit. Metab. Dis. 2010, 33, 339–346. [Google Scholar] [CrossRef]
  31. Halperin, A.; Elstein, D.; Zimran, A. Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol. Dis. 2006, 36, 426–428. [Google Scholar] [CrossRef] [PubMed]
  32. Maor, G.; Filocamo, M.; Horowitz, M. ITCH regulates degradation of mutant glucocerebrosidase: Implications to Gaucher disease. Hum. Mol. Genet. 2013, 22, 1316–1327. [Google Scholar] [CrossRef]
  33. Taguchi, Y.V.; Liu, J.; Ruan, J.; Pacheco, J.; Zhang, X.; Abbasi, J.; Keutzer, J.; Mistry, P.K.; Chandra, S.S. Glucosylsphingosine promotes alpha-synuclein pathology in mutant GBA-associated Parkinson’s disease. J. Neurosci. 2017, 37, 9617–9631. [Google Scholar] [CrossRef] [PubMed]
  34. Xu, Y.-H.; Xu, K.; Sun, Y.; Liou, B.; Quinn, B.; Li, R.-H.; Xue, L.; Zhang, W.; Setchell, K.D.; Witte, D.; et al. Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. Hum. Mol. Genet. 2014, 23, 3943–3957. [Google Scholar] [CrossRef] [PubMed]
  35. Aflaki, E.; Borger, D.K.; Moaven, N.; Stubblefield, B.K.; Rogers, S.A.; Patnaik, S.; Schoenen, F.J.; Westbroek, W.; Zheng, W.; Sullivan, P.; et al. A new glucocerebrosidase chaperone reduces alpha-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and Parkinsonism. J. Neurosci. 2016, 36, 7441–7452. [Google Scholar] [CrossRef]
  36. Benjamini, Y.; Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple hypothesis testing. J. R. Stat. Soc. B 1995, 57, 289–300. [Google Scholar] [CrossRef]
  37. Dinur, T.; Zimran, A.; Becker-Cohen, M.; Arkadir, D.; Cozma, C.; Hovakimyan, M.; Oppermann, S.; Demuth, L.; Rolfs, A.; Revel-Vilk, S. Long Term Follow-Up of 103 Untreated Adult Patients with Type 1 Gaucher Disease. J. Clin. Med. 2019, 8, 1662. [Google Scholar] [CrossRef]
  38. Do, J.; McKinney, C.; Sharma, P.; Sidransky, E. Glucocerebrosidase and its relevance to Parkinson disease. Mol. Neurodegener. 2019, 14, 36. [Google Scholar] [CrossRef]
  39. Sidransky, E.; Nalls, M.A.; Aasly, J.O.; Aharon-Peretz, J.; Annesi, G.; Barbosa, E.R.; Bar-Shira, A.; Berg, D.; Bras, J.; Brice, A.; et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N. Engl. J. Med. 2009, 361, 1651–1661. [Google Scholar] [CrossRef]
  40. Stojkovska, I.; Krainc, D.; Mazzulli, J.R. Molecular mechanisms of α-synuclein and GBA1 in Parkinson’s disease. Cell Tissue Res. 2018, 373, 51–60. [Google Scholar] [CrossRef]
  41. Argyriou, A.; Dermentzaki, G.; Papasilekas, T.; Moraitou, M.; Stamboulis, E.; Vekrellis, K.; Michelakakis, H.; Stefanis, L. Increased dimerization of alpha-synuclein in erythrocytes in Gaucher disease and aging. Neurosci. Lett. 2012, 528, 205–209. [Google Scholar] [CrossRef]
  42. Pchelina, S.; Nuzhnyi, E.; Emelyanov, A.; Boukina, T.; Usenko, T.; Nikolaev, M.; Salogub, G.; Yakimovskii, A.; Zakharova, E.Y. Increased plasma oligomeric alpha-synuclein in patients with lysosomal storage diseases. Neurosci. Lett. 2014, 583, 188–193. [Google Scholar] [CrossRef] [PubMed]
  43. Mazzulli, J.R.; Xu, Y.H.; Sun, Y.; Knight, A.L.; McLean, P.J.; Caldwell, G.A.; Sidransky, E.; Grabowski, G.A.; Krainc, D. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011, 146, 37–52. [Google Scholar] [CrossRef] [PubMed]
  44. Lerche, S.; Wurster, I.; Roeben, B.; Zimmermann, M.; Riebenbauer, B.; Deuschle, C.; Hauser, A.K.; Schulte, C.; Berg, D.; Maetzler, W.; et al. Parkinson’s Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alpha-synuclein Profiles. Mov. Disord. 2020, 35, 495–499. [Google Scholar] [CrossRef] [PubMed]
  45. Chiba-Falek, O.; Lopez, G.J.; Nussbaum, R.L. Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients. Mov. Disord. 2006, 21, 1703–1708. [Google Scholar] [CrossRef] [PubMed]
  46. Bras, J.; Paisan-Ruiz, C.; Guerreiro, R.; Ribeiro, M.H.; Morgadinho, A.; Januario, C.; Sidransky, E.; Oliveira, C.; Singleton, A. Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal. Neurobiol. Aging 2009, 30, 1515–1517. [Google Scholar] [CrossRef] [PubMed]
  47. Kalinderi, K.; Bostantjopoulou, S.; Paisan-Ruiz, C.; Katsarou, Z.; Hardy, J.; Fidani, L. Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece. Neurosci. Lett. 2009, 452, 87–89. [Google Scholar] [CrossRef]
  48. Mao, X.-Y.; Burgunder, J.-M.; Zhang, Z.-J.; An, X.-K.; Zhang, J.-H.; Yang, Y.; Li, T.; Wang, Y.-C.; Chang, X.-L.; Peng, R. Association between GBA L444P mutation and sporadic Parkinson’s disease from Mainland China. Neurosci. Lett. 2010, 469, 256–259. [Google Scholar] [CrossRef]
  49. Mitsui, J.; Mizuta, I.; Toyoda, A.; Ashida, R.; Takahashi, Y.; Goto, J.; Fukuda, Y.; Date, H.; Iwata, A.; Yamamoto, M.; et al. Mutations for Gaucher Disease Confer High Susceptibility to Parkinson Disease. Arch. Neurol. 2009, 66, 571–576. [Google Scholar] [CrossRef]
  50. Sato, C.; Morgan, A.; Lang, A.E.; Salehi-Rad, S.; Kawarai, T.; Meng, Y.; Ray, P.N.; Farrer, L.A.; George-Hyslop, P.S.; Rogaeva, E. Analysis of the glucocerebrosidase gene in Parkinson’s disease. Mov. Disord. 2005, 20, 367–370. [Google Scholar] [CrossRef]
  51. Sun, Q.-Y.; Guo, J.-F.; Wang, L.; Yu, R.-H.; Zuo, X.; Yao, L.-Y.; Pan, Q.; Xia, K.; Tang, B.-S. Glucocerebrosidase Gene L444P mutation is a risk factor for Parkinson’s disease in Chinese population. Mov. Disord. 2010, 25, 1005–1011. [Google Scholar] [CrossRef]
  52. Tan, E.-K.; Tong, J.; Fook-Chong, S.; Yih, Y.; Wong, M.-C.; Pavanni, R.; Zhao, Y. Glucocerebrosidase Mutations and Risk of Parkinson Disease in Chinese Patients. Arch. Neurol. 2007, 64, 1056–1058. [Google Scholar] [CrossRef] [PubMed]
  53. Wu, Y.-R.; Chen, C.-M.; Chao, C.-Y.; Ro, L.-S.; Lyu, R.-K.; Chang, K.-H.; Lee-Chen, G.-J. Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese. J. Neurol. Neurosurg. Psychiatry 2007, 78, 977–979. [Google Scholar] [CrossRef] [PubMed]
  54. Ziegler, S.G.; Eblan, M.J.; Gutti, U.; Hruska, K.S.; Stubblefield, B.K.; Goker-Alpan, O.; LaMarca, M.E.; Sidransky, E. Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Mol. Genet. Metab. 2007, 91, 195–200. [Google Scholar] [CrossRef] [PubMed]
  55. Neumann, J.; Bras, J.; Deas, E.; O’Sullivan, S.S.; Parkkinen, L.; Lachmann, R.H.; Li, A.; Holton, J.; Guerreiro, R.; Paudel, R.; et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease. Brain 2009, 132, 1783–1794. [Google Scholar] [CrossRef]
  56. Spitz, M.; Rozenberg, R.; Pereira Lda, V.; Reis Barbosa, E. Association between Parkinson’s disease and glucocerebrosidase mutations in Brazil. Parkinsonism Relat. Disord. 2008, 14, 58–62. [Google Scholar] [CrossRef]
  57. De Marco, E.V.; Annesi, G.; Tarantino, P.; Rocca, F.E.; Provenzano, G.; Civitelli, D.; Cirò Candiano, I.C.; Annesi, F.; Carrideo, S.; Condino, F.; et al. Glucocerebrosidase gene mutations are associated with Parkinson’s disease in southern Italy. Mov. Disord. 2008, 23, 460–463. [Google Scholar] [CrossRef]
  58. Becker-Cohen, M.; Zimran, A.; Dinur, T.; Tiomkin, M.; Cozma, C.; Rolfs, A.; Arkadir, D.; Shulman, E.; Manor, O.; Paltiel, O.; et al. A Comprehensive Assessment of Qualitative and Quantitative Prodromal Par-kinsonian Features in Carriers of Gaucher Disease-Identifying Those at the Greatest Risk. Int. J. Mol. Sci. 2022, 23, 12211. [Google Scholar] [CrossRef]
  59. Wang, Y.; Liu, L.; Xiong, J.; Zhang, X.; Chen, Z.; Yu, L.; Chen, C.; Huang, J.; Zhang, Z.; Mohmed, A.A.; et al. Glucocerebrosidase L444P mutation confers genetic risk for Parkinson’s disease in central China. Behav. Brain Funct. 2012, 8, 57. [Google Scholar] [CrossRef]
  60. Barbour, R.; Kling, K.; Anderson, J.P.; Banducci, K.; Cole, T.; Diep, L.; Fox, M.; Goldstein, J.M.; Soriano, F.; Seubert, P.; et al. Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood. Neurodegener. Dis. 2008, 5, 55–59. [Google Scholar] [CrossRef]
  61. Zanzoni, A.; Marchese, D.; Agostini, F.; Bolognesi, B.; Cirillo, D.; Botta-Orfila, M.; Livi, C.M.; Rodriguez-Mulero, S.; Tartaglia, G.G. Principles of self-organization in biological pathways: A hypothesis on the autogenous association of alpha-synuclein. Nucleic Acids Res. 2013, 41, 9987–9998. [Google Scholar] [CrossRef] [PubMed]
  62. Yun, S.P.; Kim, D.; Kim, S.; Kim, S.; Karuppagounder, S.S.; Kwon, S.-H.; Lee, S.; Kam, T.-I.; Lee, S.; Ham, S.; et al. α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. Mol. Neurodegener. 2018, 13, 1. [Google Scholar] [CrossRef] [PubMed]
Biomolecules 13 00644 g001
Figure 1. Lyso-Gb1 concentration (ng/mL) in GD patients and GBA1 carriers compared to healthy control subjects. IQR represents the interquartile range.
Figure 1. Lyso-Gb1 concentration (ng/mL) in GD patients and GBA1 carriers compared to healthy control subjects. IQR represents the interquartile range.
Biomolecules 13 00644 g001
Biomolecules 13 00644 g002
Figure 2. Alpha synuclein mRNA level. The SNCA gene expression level among GD1 and GD3 patients was compared to that among GBA1 mutation carriers and healthy control subjects. Results are presented as the change-in-cycling-threshold using the ΔCq method.
Figure 2. Alpha synuclein mRNA level. The SNCA gene expression level among GD1 and GD3 patients was compared to that among GBA1 mutation carriers and healthy control subjects. Results are presented as the change-in-cycling-threshold using the ΔCq method.
Biomolecules 13 00644 g002
Biomolecules 13 00644 g003
Figure 3. Total α-SNCA protein level (ng/mL) among GD1 and GD3 patients compared to GBA1 mutation carriers and healthy control subjects. IQR represents the interquartile range.
Figure 3. Total α-SNCA protein level (ng/mL) among GD1 and GD3 patients compared to GBA1 mutation carriers and healthy control subjects. IQR represents the interquartile range.
Biomolecules 13 00644 g003
Biomolecules 13 00644 g004
Figure 4. Oligomer α-SNCA protein concentration (ng/mL) among GD1 and GD3 patients compared to GBA1 mutation carriers and healthy control subjects. IQR represents the interquartile range.
Figure 4. Oligomer α-SNCA protein concentration (ng/mL) among GD1 and GD3 patients compared to GBA1 mutation carriers and healthy control subjects. IQR represents the interquartile range.
Biomolecules 13 00644 g004
Table 1. GBA1 pathogenic variants in GD1 patients.
Table 1. GBA1 pathogenic variants in GD1 patients.
Number of PatientsCommon Variant NameDNA Nucleotide ChangeProtein Change
28N370S/L444Pc.1226A>G
c.1448T>C		p.Asn409Ser
p.Leu483Pro
6N370S/
others		c.1226A>Gp.Asn409Ser
2N370S/N370Sc.1226A>Gp.Asn409Ser
2G377S/G377Sc.1246G>Ap.Gly416Ser
1N370S/
G377S		c.1226A>G
c.1246G>A		p.Asn409Ser
p.Gly416Ser
1N370S/84GGc.1226A>G
c.84dupG		p.Asn409Ser
p.Leu29AlafsTer18
1N370S/R496Hc.1226A>G
c.1604G>A		p.Asn409Ser
p.Arg535His
1R433S/R433Sc.1416A>Tp.Arg444Ser
1D438N/R87Wc.1312G>A
c.259C>T		p.Asp438Asn
p.Arg87Trp
1D448G/R202Xc.1343A>G
c.604C>T		p.Asp448Gly
p.Arg202X
1R48W/84GGc.259C>T
c.84dupG		p.Arg87Trp
p.Leu29AlafsTer18
1R48W/R48Wc.259C>Tp.Arg87Trp
184GG/
Other		c.84dupGp.Leu29AlafsTer18
Table 2. Patients’ characteristics. Abbreviations: α-SNCA—alpha-synuclein; GD—Gaucher disease; Lyso-Gb1—Glucosylsphingosine; SNCA—gene coding alpha-synuclein.
Table 2. Patients’ characteristics. Abbreviations: α-SNCA—alpha-synuclein; GD—Gaucher disease; Lyso-Gb1—Glucosylsphingosine; SNCA—gene coding alpha-synuclein.
Healthy ControlsGBA1 Mutation CarriersGD1GD3
n16194718
Sex, F/M10/614/528/1912/8
Age in years, median (range)44.552 (13–64)40 (9–71)30 (22–62)
Lyso-Gb1 (ng/mL), median (range)8.49 (4.82–46.73)7.51 (4.26–46.73)71.5 (22.4–950.9)64.55 (9.14–693.8)
SNCA mRNA level (2−ΔcT), median (range)0.83 (0.08–16.38)4.16 (0.02–161.42)0.47 (0.01–134.42)77.48 (0.04–141.72)
Total α-SNCA concentration (ng/mL), median (range)1.34 (0.16–37.48)0.53 (0.16–21.76)0.16 (0.16–20)0.92 (0.16–20)
Oligomer α-SNCA concentration (ng/mL), median (range)2.08 (0.96–4.73)1.69 (1.03–3.33)1.76 (0.76–4.01)1.857(0.76–3.03)
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Dubiela, P.; Szymańska-Rożek, P.; Eljaszewicz, A.; Lipiński, P.; Hasiński, P.; Giersz, D.; Walewska, A.; Tynecka, M.; Moniuszko, M.; Tylki-Szymańska, A. Alpha-Synuclein mRNA Level Found Dependent on L444P Variant in Carriers and Gaucher Disease Patients on Enzyme Replacement Therapy. Biomolecules 2023, 13, 644. https://doi.org/10.3390/biom13040644

AMA Style

Dubiela P, Szymańska-Rożek P, Eljaszewicz A, Lipiński P, Hasiński P, Giersz D, Walewska A, Tynecka M, Moniuszko M, Tylki-Szymańska A. Alpha-Synuclein mRNA Level Found Dependent on L444P Variant in Carriers and Gaucher Disease Patients on Enzyme Replacement Therapy. Biomolecules. 2023; 13(4):644. https://doi.org/10.3390/biom13040644

Chicago/Turabian Style

Dubiela, Paweł, Paulina Szymańska-Rożek, Andrzej Eljaszewicz, Patryk Lipiński, Piotr Hasiński, Dorota Giersz, Alicja Walewska, Marlena Tynecka, Marcin Moniuszko, and Anna Tylki-Szymańska. 2023. "Alpha-Synuclein mRNA Level Found Dependent on L444P Variant in Carriers and Gaucher Disease Patients on Enzyme Replacement Therapy" Biomolecules 13, no. 4: 644. https://doi.org/10.3390/biom13040644

APA Style

Dubiela, P., Szymańska-Rożek, P., Eljaszewicz, A., Lipiński, P., Hasiński, P., Giersz, D., Walewska, A., Tynecka, M., Moniuszko, M., & Tylki-Szymańska, A. (2023). Alpha-Synuclein mRNA Level Found Dependent on L444P Variant in Carriers and Gaucher Disease Patients on Enzyme Replacement Therapy. Biomolecules, 13(4), 644. https://doi.org/10.3390/biom13040644

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop